RESTON, Va., July 10, 2024 — Rohirrim, the leading Request for Proposal (RFP) AI automation platform, announced today that Bessemer Venture Partners and IBM Ventures made strategic investments in the company. These investments will further fuel Rohirrim’s mission to help businesses grow by streamlining and strengthening their RFP response strategy. Rohirrim’s RohanRFP platform unlocks the power of organizations’ data and uses its patented generative AI technology to help them create long-form, complex documents in a fraction of the time.

Since announcing its Series A round led by Insight Partners in 2023, the company has experienced rapid growth. Over the past 12 months, Rohirrim has seen a 400% growth in customers. One customer reported that the research that would normally take a team of SMEs 6 days to complete now takes 6 hours using RohanRFP. Additionally, Rohirrim was selected to participate in the Microsoft Pegasus Program, which offers additional support to startups to uncover leads, drive sales, and accelerate growth. Mike Papay, Cybersecurity and Risk titan, joined Rohirrim’s Board of Advisors as Chairman, and Dave O’Hara, former Microsoft CFO, was recently appointed to their Board of Directors.

“After countless nights of missing precious family moments to work on RFP responses, in 2021, I began working on a better way,” said Steven Aberle, Rohirrim CEO and Founder. “RohanRFP has delivered profound efficiencies to our customers, efficiencies that have the potential to be game changers for organizations. This is the core of who we are and what drives us every day as we execute our mission: to reimagine work and deliver higher win rates, increased volume, and revenue growth for all our customers.” 

“When we looked at companies in the RFP automation space, Rohirrim stood out as the clear market leader for commercial and public sector organizations that deal with lengthy and complex proposal creation processes and care about best-in-class data security. Rohirrim’s technology has the potential to provide meaningful business growth to organizations, and we believe they have the team, technology, and infrastructure in place to make it happen,” said Aia Sarycheva, Investor at Bessemer Partner Ventures.

By generating the first draft of an RFP in a fraction of the time, proposal teams can focus on what they do best: storytelling and persuasion – making their responses more compelling and competitive. RohanRFP can profoundly impact an organization’s ability to grow by reducing costs and increasing the volume of RFP submissions.

“As an AI native platform, Rohirrim is uniquely poised to deliver on early promises of generative AI while protecting an organization’s proprietary data – aligning to IBM’s vision for helping organizations harness the power of AI with safety and responsibility at the forefront. Rohirrim brings incredible efficiencies to proposal writing with AI content creation,” said Tom Whiteaker, Partner at IBM Ventures.

In addition to being investors in the company, the IBM team experienced firsthand the power of the RohanRFP platform as early adopters. They immediately saw the efficiency gains and impact on their organization. IBM Ventures Partner Tom Whiteaker will join as a board observer alongside Bessemer Venture Partners’ Mike Droesh and Aia Sarycheva.

About Bessemer Venture Partners

Bessemer Venture Partners helps entrepreneurs lay strong foundations to build and forge long-standing companies. With more than 145 IPOs and 300 portfolio companies in the enterprise, consumer and healthcare spaces, Bessemer supports founders and CEOs from their early days through every stage of growth. Bessemer’s global portfolio has included Pinterest, Shopify, Twilio, Yelp, LinkedIn, PagerDuty, DocuSign, Wix, Fiverr, and Toast and has more than $18 billion of assets under management. Bessemer has teams of investors and partners located in Tel Aviv, Silicon Valley, San Francisco, New York, London, Hong Kong, Boston, and Bangalore. Born from innovations in steel more than a century ago, Bessemer’s storied history has afforded its partners the opportunity to celebrate and scrutinize its best investment decisions (see Memos) and also learn from its mistakes (see Anti-Portfolio).

About Rohirrim

Rohirrim uses its patented, first-ever, organization-specific generative-AI technology to develop groundbreaking products that aim to reimagine how people work, particularly when it comes to time-intensive, repetitive, and manual tasks. Rohirrim was born out of the need to improve the work-life balance of proposal teams and has stayed true to its vision in the continuous pursuit of new ways to make people’s work lives better. Learn more at www.rohirrim.ai

Media Contact:
Farah van Caloen
[email protected]

SOURCE Rohirrim

SAN FRANCISCO, July 10, 2024 — MeetRecord, a Revenue Automation platform that specializes in sales coaching, has bagged several awards from G2. Known for its ability to capture key insights from every sales conversation and support informed decision-making, MeetRecord received over 8 badges in 4 different categories, showcasing its excellence in sales coaching and customer experience.

Key awards include badges for “Ease of Doing Business, Ease of Admin, and High Performer.” These badges highlight MeetRecord’s easy-to-use and effective solutions, which help businesses boost their sales performance and simplify administrative tasks.

MeetRecord’s sales coaching tools help sales teams perform better by using advanced analytics and easy-to-understand reports. These features allow sales leaders to find strengths and areas for improvement, promoting continuous growth and success.

Customer experience is a major focus for MeetRecord. This dedication is reflected in the High Performer badge from G2, which shows the company’s ability to provide top-quality services that meet clients’ changing needs. The Ease of Doing Business badge emphasizes how simple it is to integrate MeetRecord into existing workflows, enhancing productivity and ROI.

“Our goal has always been to provide great value to our customers through innovative solutions and outstanding service,” said Paras Jain, Co-founder & CCO, of MeetRecord. “By focusing on our customers’ success, we create strong, beneficial relationships. The recent G2 awards, including Ease of Doing Business, Ease of Admin, and High Performer, prove our commitment to excellence and customer satisfaction.”

MeetRecord’s platform supports sales teams with real-time feedback and actionable insights, helping them refine their strategies and achieve their targets. The G2 badges, especially High Performer and Ease of Doing Business, highlight MeetRecord’s success in delivering these benefits.

As MeetRecord continues to grow and innovate, the company remains dedicated to providing top-notch solutions that meet clients’ evolving needs. The recent G2 recognitions inspire MeetRecord to keep pushing the limits of sales intelligence and customer experience.

For more information about MeetRecord, visit – https://www.meetrecord.com

About MeetRecord

MeetRecord‘s Revenue Automation Solution empowers Sales teams with streamlined deal flow, intuitive pipeline visualization, and personalized AI Sales coaching. It enhances sales collaboration, accelerates deal conversion, offers visibility into conversations, and provides comprehensive deal summaries, ensuring peak performance. Trusted by industry leaders like Gymlaunch, Jisr, Fyle, Kisi and many more.

SOURCE MeetRecord Inc.

The company’s innovative controller-less orchestration software harnesses the power of Linux to quickly execute modern data infrastructure for data-intensive workloads using a declarative interface that makes it easy to deploy a wide variety of applications in hybrid and multi-cloud environments. Volumez will use the funds to continue to expand its customer base and grow its business operations in the U.S. and EMEA while maintaining R&D execution in Israel.

“This round of funding is a strong commitment of our existing and new strategic investors to support our business growth plans, the partnerships with the major cloud providers (Amazon Web Services, Microsoft Azure, and Oracle Cloud), and our additional customers,” said Amir Faintuch, CEO of Volumez. “This funding will enable us to broaden our cloud services to additional AI and machine learning workloads, expanding our solution offerings on the Volumez platform.”

“Cloud is the new frontier for storage revolution, and we are betting on Volumez to lead the way as the pioneer of composable data infrastructure for the cloud,” said Samsung Ventures representative. “No other vendor is delivering ultra-fast, guaranteed performance at significant cost savings in the form of “data infrastructure as code” that automates storage management to reduce risks, control cloud costs, and accelerate application deployment.”

“We are excited to continue our support for Volumez as they accelerate their customer growth and strategic product development,” said Byron Knight, President at KDT. “KDT is committed to empowering visionary entrepreneurs who are building transformative companies and revolutionizing industries. Volumez exemplifies this by unlocking the potential of its unique cloud-aware architecture in the data infrastructure domain, driving innovation, and setting new benchmarks for enterprise software and technological advancement.”

About Volumez 

Volumez is a revolutionary composable data infrastructure company businesses employ to realize the true potential of their data. With its innovative controller-less architecture, Volumez tackles latency and scalability challenges by establishing direct Linux data paths, ensuring exceptional performance and resiliency. Driven by cutting-edge technology and a customer-centric approach, Volumez offers comprehensive solutions that streamline data workflows, enhance data quality, and drive informed decision-making.

Discover more at volumez.com.

Photo – https://mma.prnewswire.com/media/2458123/Volumez_Series_A.jpg

SOURCE Volumez

SAN FRANCISCO, July 10, 2024 — Therapeutic delivery platform Granza Bio announced today the close of its oversubscribed $7.14M Seed led by Felicis and Refactor, along with Y Combinator and notable angel investors.

Founded in 2024 by a team of cancer and immunology researchers at the University of Oxford, Granza Bio utilizes the discovery of “attack particles,” a powerful suite of weapons in the immune system’s arsenal that can fight diseases such as cancers, autoimmunity and infections.

“With attack particles, we discovered a new feature of the immune system that has the potential to transform the therapeutic landscape. They offer the power of cellular therapies with the off-the-shelf ease of antibody-based drugs,” said Granza Bio co-founder Michael Dustin, Professor of Molecular Immunology at Oxford.

However, the team realized they lacked an effective delivery system for packaging and delivering attack particles to specific tissues.

To solve this problem, Granza Bio’s platform offers a unique delivery system that focuses on three key areas:

1) The ability to deliver a variety of cargo types (such as RNAs, proteins, and attack particles)
2) The ability to deliver to a range of tissue sites
3) Overcoming immunological activation triggered by the delivery vehicle

“We are developing a series of precision delivery shells that can encompass and direct any therapeutic cargo to the correct destination in our body. This work will be fundamental for turning promising discoveries in genetic medicine and cancer therapeutics into impactful treatments for patients,” said Granza co-founder and Chief Executive Officer, Dr. Ashwin Nandakumar.

“Through the development of a comprehensive library of engineered shells, we aim to tackle the challenges of tropism, immunogenicity, and stability head-on. Our strength lies in the interdisciplinary nature of our team, spanning fundamental immunology to industrial manufacturing and scale-up processes. This is a pivotal moment for the field of drug delivery therapeutics and we are at the forefront of this transformation,” said Dr. Ashwin Jainarayanan, Granza Bio’s Chief Scientific Officer.

Dr. Nandakumar, CEO, holds a PhD in Oncology, has previously set up clinical trials, and brings oncology start-up experience. Dr. Jainarayanan, CSO, is a PhD in Interdisciplinary Bioscience and was recently selected as a Schmidt Science Fellow. Prof. Dustin is also the director of research at the Kennedy Institute of Rheumatology at Oxford.

“The immune system is nature’s most powerful mechanism for biological remediation. By improving the delivery and specificity of naturally occurring attack particles, Granza Bio can unlock a new world of capabilities for oncological and immunological diseases,” said Tobi Coker, Deal Partner at Felicis. “Granza encompasses a unique combination of significant scientific advancements, a founding team with complementary skills, and deep domain expertise. We are thrilled to be working with them.”

“I focus on finding technical founders who are experts in their fields and are magnets for customers, talent, and investors. Both Ashwins really fit that perfectly, in my opinion, as they build a better delivery mechanism for a variety of therapeutics,” said Zal Bilimoria, founding partner at Refactor.

The investment round also includes participation from other investors including Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, and North South Ventures. Notable angels joined the round including Richard Aberman (former YC Visiting Group Partner), JJ Fliegelman (former YC Visiting Group Partner), Eric Migicovsky (former YC Group Partner), Eric Eldon (former editor of TechCrunch), Eli Brown (founder, Guilded), Eoghan Mccabe (founder, Intercom), Benjamin Bryant (co-founder, Earbits), Yotam Rosenbaum (co-founder, Earbits), Will Olsen (co-founder, Engage Bio) and Joel Meyer.

For partnership and licensing opportunities, please reach out to [email protected].
Learn more at granzabio.com.

About Granza Bio 
Founded in 2024, Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s powerful suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these “attack particles” against a range of diseases such as cancer, autoimmune disorders, and infections. The company has recently raised a $7M+ Seed round led by Felicis and Refactor, along with Y Combinator and notable ventures and angel investors. Granza Bio was co-founded by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, researchers from the University of Oxford. Learn more at granzabio.com. Visit our linkedin.  

SOURCE Granza Bio Corporation

SEOUL, South Korea, July 10, 2024 — AIRS Medical, a pioneering force in artificial intelligence (AI) and robotics for healthcare applications, today announced the completion of its Series C funding round, securing $20 million from seven institutional investors in Korea. The investment, led by BSK Investment and Shinyoung Securities, underscores confidence not only in the company’s flagship product, SwiftMR™, but also in its larger mission to revolutionize preventive healthcare through technology innovation.

Transforming MRI

SwiftMR™ uses deep learning technology to enhance magnetic resonance imaging (MRI) scan speeds by as much as 50% compared to the standard of care.* On average, radiology centers and hospitals that integrate SwiftMR™ achieve a 38% increase in patient throughput and a 22% reduction in business hours, leading to $44,000 per month in additional revenue and an $8,000 reduction in monthly operating costs.

SwiftMR™ is a scan time reduction solution with whole pulse-sequence coverage and true super resolution. This cutting-edge technology has set the standard in diagnostic imaging, helping to address critical roadblocks radiology centers and hospitals face, such as long patient wait times and the downstream effects of delayed diagnoses.

Improving patient outcomes

A frequent problem in healthcare is the delayed diagnosis of patients, often after symptoms have advanced. This, along with resource shortages, results in worse outcomes.

AIRS Medical is paving the way to detect diseases proactively, before they manifest. Through AI and robotics, AIRS Medical is democratizing the best diagnostics and prognostics, reducing costs and increasing the accessibility of MRI scans. Ultimately, this empowers patients with conditions such as dementia, stroke, and cancer to receive early diagnoses and improve their chances of better health.

Expanding access to care

In its quest to deliver the highest-quality preventive care to all, AIRS Medical is rapidly expanding. Backed by a talented team, SwiftMR™ was initially launched in Korea in 2021. By 2023, the technology had successfully entered the United States and Europe, markets that now account for over half of the company’s annual recurring revenue (ARR).

“We’re thrilled to receive this substantial support from our investors,” said Hyeseong Lee, CEO of AIRS Medical. “This funding will empower us to increase access to preventive healthcare services and create a healthier future for people around the globe.”

Building a better future

With this latest round of funding, AIRS Medical is poised to accelerate its growth and innovate beyond the award-winning SwiftMR™. The company plans to expand its presence in international markets, invest in research and development, and ultimately improve patient outcomes worldwide.

For more information about AIRS Medical, visit https://airsmed.com/en/.

*For investigational purposes in countries outside of the United States, South Korea, Canada, Brazil, Japan, Taiwan, Malaysia, Saudi Arabia, UAE, Thailand, Vietnam, and Indonesia. FDA 510(k)-cleared to support images with scan time reduction by up to 50% in the United States.

For press inquiries or questions about this release please contact:

Ashley Guidace
AIRS Medical
Director of Global Marketing
[email protected] 

SOURCE AIRS Medical

SINGAPORE, July 10, 2024 — ThirdFi.org, a web3 infrastructure protocol that empowers web3 users with identity and developers with api and sdk, has raised $2m in token financing investments from world class accelerators and pre-seed investors; Techstars, Chainlink, Outlier Ventures, Alphabit Capital and more.

This raises ThirdFi’s FDV to $20m after building in the bear market for the last 2 years. With its leadership and experienced team, ThirdFi is transforming to a modular web3 infrastructure protocol that focuses on AI applications on decentralized finance (DeFi).

Since its founding in 2022 and graduating from Techstars Web3 accelerator program, ThirdFi has been on the mission to empower developers and web3 startups with dev-toolings, API and sdk, building “picks and shovel”, to accelerate the adoption of DeFi to 1 billion users. In the last 2 years, ThirdFi has amassed more than 170,000 users with more than $46 million on mainnet and L2 transactions by partnering with more than 50 web3 communities and protocols.

With the v2 launch that targets web3 users data to empower AI builders, ThirdFi is poised to grow in the upcoming blockchain AI market that is expected to grow to $2.7 billion by 2031 at a 25% CAGR yearly. The v2 creates even a better product-market fit to capture the growth of developers and users in AI applications such as AI agents, models and signals.

Users can now participate in the early access of Data-to-Earn campaign to gain data points for future airdrop allocations and contribute to the blockchain AI movement where users now own their identity and data points. These data points are NFT-bound and tradeable in the future making it a web3-centric approach and empowering users to own their data.

About ThirdFi.org
Website: https://www.thirdfi.org/
Twitter: https://x.com/thirdfiorg
Telegram: https://t.me/thirdfi_org

SOURCE ThirdFi

NEW TOWN, Pa., July 10, 2024 — Miravast Asset Management LLC, a leading vertically integrated investment manager with deep experience underwriting longevity risk and investing in life settlements is pleased to share that it recently completed fundraising for Miravast ILS Credit Opportunities II LP (“Fund II”) with $346 million of fund commitments.  

“Closing Fund II represents an important milestone for Miravast. We continue to believe Miravast offers institutional investors an unparalleled team of medical underwriting and actuarial experts. The LP support we are fortunate to have for Fund II further exemplifies the confidence that the institutional LP community has in the Miravast team,” said Dave Beckelman, Chief Executive Officer. 

“As with its predecessor, Fund II has a global institutional investor base.  We are grateful to have support from existing and new institutional LP’s as we execute our strategy.  We have invested a portion of Fund II’s committed capital and will continue to leverage our in-house expertise as we pursue additional investments,” said Dave Cherkas, Executive Vice President.  

Schule Roth & Zabel LLP served as legal counsel for Miravast Asset Management and Fund II. 

About Miravast Asset Management LLC

Founded in 2012, Miravast (www.miravast.com) is a vertically integrated asset management firm with approximately $1.2 billion of assets under management. Miravast’s experience in life insurance product design and medical underwriting, coupled with our perspective on investment structures, allows us to help institutional investors navigate the complexities of investing in longevity risk, chiefly life settlements. 

Our in-house medical underwriters utilize a proprietary view based on a significant population of settled life insurance policies.  Additionally, our underwriting model provides interest alignment that differs from the outsourced volume-based models most often utilized by the broader market. Our underwriting and life insurance product experience can lead to significant differences in our view compared to the market’s view. We seek to identify opportunities that others miss and avoid those that others may overvalue while still acquiring assets at market value.  

Miravast team members have led the investment of approximately $6 billion since 2001. We advise separately managed accounts and pooled investment funds for pensions, endowments, insurance companies, and family offices. 

SOURCE Miravast LLC

KNOXVILLE, Tenn., July 9, 2024 — Regal (the “Company”) announced today that it has successfully completed a $250 million capital raise. With this investment, Regal is well positioned for accelerated growth through improvements to existing assets, and digital enhancements to the moviegoing experience.

“Regal has been executing on its business plan with results through the first quarter that exceeded our expectations providing one of the strongest balance sheets in the business,” stated Thomas Song, Chief Financial Officer for Regal. “As we invest in providing the best moviegoing experience, our customers will enjoy in-theatre improvements coupled with a very compelling movie slate through the end of the year.”

Song continued, “With the strong support from our existing investors and real estate partners, Regal is well positioned to invest in growth opportunities with highly accretive investments including brand-new luxury recliners in the United States and digital enhancements for our loyal customers. As we identify theatres for these improvements, we encourage our landlords to also reach out with interest for their respective locations.”

The capital raise will be used to upgrade existing Regal theatres in concert with respective real estate partners, including investments in luxury recliners and additional improvements to the moviegoing experience through upgrades to Regal’s digital channels including the website and app. Construction has been initiated with over 30 locations completed during 2025.

About Regal
Regal operates one of the largest and most geographically diverse theatre circuits in the United States, consisting of 5,774 screens in 425 theatres in 41 states along with the District of Columbia and Guam as of June 30, 2024. We believe that the size, reach and quality of the company’s theatre circuit provides its patrons with a convenient and enjoyable moviegoing experience. Additional information is available online at REGmovies.com.

Media Contacts
Richard M. Grover
Head of Marketing
Regal
(865) 925-9539

SOURCE Regal

RESEARCH TRIANGLE PARK, N.C., July 9, 2024 — Dental Innovation Alliance (DIA), a leading venture capital firm dedicated to advancing dental technologies, announces its latest strategic investment in Alta Smiles. Alta Smiles is at the forefront of innovation in hidden orthodontics and is set to disrupt the industry with its unique approach to patient care and technology. DIA’s investment marks Alta Smiles’ first institutional financing. Previously self-funded through a select group of strategic individual investors, Alta Smiles has now secured support from DIA, bringing a wealth of industry expertise and connections to the table.

“Our investment in Alta Smiles highlights DIA’s commitment to identifying and supporting technologies that are transforming dental care. Alta Smiles’ novel orthodontic technology significantly benefits both patients and providers. We believe Alta Smiles is uniquely positioned to drive the continued consumerization of dentistry and meet growing patient demand for aesthetically oriented orthodontic solutions,” shares Doug Brown, Co-Founder and Managing Director of DIA.

Alta Smiles’ orthodontic treatment is completely hidden, comfortable, and convenient. The company’s C⁵ Hidden Orthodontics technology utilizes state-of-the-art materials and design to discreetly align teeth without the need for traditional metal brackets. It also integrates digital monitoring and remote consultation capabilities into its treatment process, allowing for flexibility and convenience in managing orthodontic care from anywhere. By integrating advanced technology with personalized care, Alta Smiles ensures that orthodontic treatment is seamless, stress-free, and more accessible than ever before.

“We are thrilled to welcome DIA as a strategic partner. DIA’s deep industry knowledge and vast network will be instrumental in accelerating our growth and expanding our market presence. Their investment is not just a vote of confidence in our vision but also a validation of the transformative impact we aim to make in orthodontic care,” says Gary Giegerich, Founder and CEO of Alta Smiles.

About DIA
Dental Innovation Alliance (DIA) is a close group of dental industry executives that funds, advises and propels the success of early-stage companies building the future of dentistry through technology. Its investor base includes executives and experts from some of the largest and most innovative dental support organizations and other dental businesses. DIA has offices in New York, Nashville, and Research Triangle Park, NC.

About Alta Smiles, LLC
Founded in 2019 and guided by a world-class board of advisors that includes leading investors and executives from the dental and healthcare industries, Alta Smiles is a technology and services company poised to transform the delivery of orthodontic care. Our unique patented and patent-pending technologies and methodologies create an entirely new category of orthodontic treatment with C⁵ Hidden Orthodontics. This innovative approach is preferred by patients and can be delivered by any dental or orthodontic office with a high level of expertise and confidence. In addition, V5x Dental Images leverages the most advanced technology for seamless in-office diagnostic images and time-saving remote patient monitoring. Alta Smiles is opening the door for more people to have amazing smiles.

SOURCE Dental Innovation Alliance (DIA)